DECIPHERA PHARMACEUTICALS IN (DCPH) Stock Analyst Ratings
USA - NASDAQ:DCPH - US24344T1016 - Common Stock
25.59 USD
+0.02 (+0.08%)
25.61 USD
+0.02 (+0.08%)
ChartMill assigns a Buy % Consensus number of 71% to DCPH. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 27.25. This target is 6.47% above the current price.
DCPH was analyzed by 16 analysts. The buy percentage consensus is at 71. So analysts seem to be have mildly positive about DCPH.
In the previous month the buy percentage consensus was at a similar level.
DCPH was analyzed by 16 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-04-30 | Guggenheim | Downgrade | Buy -> Neutral |
| 2024-04-30 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2024-04-30 | Barclays | Upgrade | Underweight -> Equal-Weight |
| 2024-04-29 | JonesTrading | Downgrade | Buy -> Hold |
| 2024-04-29 | Jefferies | Downgrade | Buy -> Hold |
| 2024-03-20 | JP Morgan | Maintains | Neutral -> Neutral |
| 2024-02-07 | Stifel | Maintains | Buy -> Buy |
| 2023-11-20 | JP Morgan | Reiterate | Neutral |
| 2023-10-31 | JonesTrading | Upgrade | Hold -> Buy |
| 2023-10-31 | Stifel | Maintains | Buy -> Buy |
| 2023-10-31 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-10-30 | Piper Sandler | Upgrade | Neutral -> Overweight |
| 2023-08-10 | Stifel | Upgrade | Hold -> Buy |
| 2023-08-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-05 | JMP Securities | Reiterate | Market Outperform |
| 2023-05-04 | JMP Securities | Reiterate | Market Outperform |
| 2023-03-15 | JMP Securities | Reiterate | Market Outperform |
| 2023-02-08 | SVB Leerink | Reiterate | Outperform |
| 2023-02-08 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-02-07 | SVB Leerink | Maintains | Outperform |
| 2023-01-25 | Cowen & Co. | Maintains | Outperform |
| 2023-01-06 | JonesTrading | Upgrade | Sell -> Hold |
| 2023-01-04 | Guggenheim | Upgrade | Neutral -> Buy |
| 2023-01-04 | SVB Leerink | Maintains | Outperform |
| 2023-01-04 | Barclays | Maintains | Underweight |
| 2022-09-27 | Stifel | Maintains | Hold |
| 2022-09-12 | SVB Leerink | Maintains | Outperform |
| 2022-09-12 | HC Wainwright & Co. | Maintains | Buy |
| 2022-08-29 | Cowen & Co. | Initiate | Outperform |
| 2022-08-05 | JMP Securities | Upgrade | Market Perform -> Market Outperform |
DECIPHERA PHARMACEUTICALS IN / DCPH FAQ
What is the price target for DCPH stock?
16 analysts have analysed DCPH and the average price target is 27.25 USD. This implies a price increase of 6.47% is expected in the next year compared to the current price of 25.59.
Can you provide the consensus rating for DECIPHERA PHARMACEUTICALS IN stock?
The consensus rating for DECIPHERA PHARMACEUTICALS IN (DCPH) is 71.25 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover DECIPHERA PHARMACEUTICALS IN (DCPH) stock?
The number of analysts covering DECIPHERA PHARMACEUTICALS IN (DCPH) is 16.